KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
M. Scheffler,M. Dugan,M. M. Saleh,S. Koleczko,J. Bragelmann,C. Arolt,L. Nogova,R. Riedel,S. Michels,A. Eisert,R. Fischer,H. Scharpenseel,J. P. Weber,A. H. Scheel,S. Merkelbach-Bruse,R. Buttner,F. Lafleur,R. Wild,L. Catanzariti,A. M. Hillmer,J. Wolf
